Technical Analysis for HOWL - Werewolf Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Jack-in-the-Box Bearish | Bearish Swing Setup | -1.62% | |
| Stochastic Buy Signal | Bullish | -1.62% | |
| Inside Day | Range Contraction | -1.62% | |
| Wide Bands | Range Expansion | -1.62% | |
| Lower Bollinger Band Touch | Weakness | -1.62% | |
| Oversold Stochastic | Weakness | -1.62% |
| Alert | Time |
|---|---|
| Down 1% | about 15 hours ago |
| Gap Up Closed | about 15 hours ago |
| Reversed from Up | about 15 hours ago |
| 60 Minute Opening Range Breakdown | about 16 hours ago |
| 1.5x Volume Pace | about 20 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 05/08/2024
Werewolf Therapeutics, Inc. Description
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It offers PREDATOR, a platform of protein engineering technology to design and engineer the future of immuno-oncology biotherapeutics for patients. The company's lead product candidates include WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. It also develops WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Solid Tumors Health Sciences Treatment Of Cancer Cancer Immunotherapy Lymphoma Hematologic Malignancies Advanced Solid Tumors Metastatic Solid Tumors
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 8.1939 |
| 52 Week Low | 1.5735 |
| Average Volume | 178,820 |
| 200-Day Moving Average | 4.08 |
| 50-Day Moving Average | 5.93 |
| 20-Day Moving Average | 5.84 |
| 10-Day Moving Average | 5.42 |
| Average True Range | 0.52 |
| RSI (14) | 37.11 |
| ADX | 17.6 |
| +DI | 15.07 |
| -DI | 25.05 |
| Chandelier Exit (Long, 3 ATRs) | 5.34 |
| Chandelier Exit (Short, 3 ATRs) | 5.95 |
| Upper Bollinger Bands | 7.04 |
| Lower Bollinger Band | 4.63 |
| Percent B (%b) | 0.09 |
| BandWidth | 41.23 |
| MACD Line | -0.28 |
| MACD Signal Line | -0.13 |
| MACD Histogram | -0.1507 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.74 | ||||
| Resistance 3 (R3) | 5.82 | 5.62 | 5.59 | ||
| Resistance 2 (R2) | 5.62 | 5.39 | 5.57 | 5.54 | |
| Resistance 1 (R1) | 5.23 | 5.25 | 5.13 | 5.15 | 5.49 |
| Pivot Point | 5.03 | 5.03 | 4.98 | 4.98 | 5.03 |
| Support 1 (S1) | 4.64 | 4.80 | 4.54 | 4.56 | 4.21 |
| Support 2 (S2) | 4.44 | 4.66 | 4.39 | 4.16 | |
| Support 3 (S3) | 4.05 | 4.44 | 4.11 | ||
| Support 4 (S4) | 3.97 |
